These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 17263584)

  • 1. Trends in the development and approval of monoclonal antibodies for viral infections.
    Reichert JM
    BioDrugs; 2007; 21(1):1-7. PubMed ID: 17263584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiviral humanized and human monoclonal antibodies].
    Lashkevich VA
    Vopr Virusol; 2011; 56(5):4-8. PubMed ID: 22171470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies against viruses and bacteria: a survey of patents.
    Xiao X; Dimitrov DS
    Recent Pat Antiinfect Drug Discov; 2007 Nov; 2(3):171-7. PubMed ID: 18221173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond.
    Chaudhuri S; Symons JA; Deval J
    Antiviral Res; 2018 Jul; 155():76-88. PubMed ID: 29758235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The growth and potential of human antiviral monoclonal antibody therapeutics.
    Marasco WA; Sui J
    Nat Biotechnol; 2007 Dec; 25(12):1421-34. PubMed ID: 18066039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human respiratory syncytial virus and other viral infections in infants receiving palivizumab.
    Boivin G; Caouette G; Frenette L; Carbonneau J; Ouakki M; De Serres G
    J Clin Virol; 2008 May; 42(1):52-7. PubMed ID: 18164233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab and RSV prevention.
    Carnegie C
    Arch Dis Child; 2000 Jul; 83(1):87. PubMed ID: 10960341
    [No Abstract]   [Full Text] [Related]  

  • 8. Palivizumab and RSV prevention.
    Lenney W
    Arch Dis Child; 2000 Jul; 83(1):87. PubMed ID: 10960342
    [No Abstract]   [Full Text] [Related]  

  • 9. A molecular perspective for the development of antibodies against the human respiratory syncytial virus.
    Loaiza RA; Ramírez RA; Sepúlveda-Alfaro J; Ramírez MA; Andrade CA; Soto JA; González PA; Bueno SM; Kalergis AM
    Antiviral Res; 2024 Feb; 222():105783. PubMed ID: 38145755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab: where to from here?
    Georgescu G; Chemaly RF
    Expert Opin Biol Ther; 2009 Jan; 9(1):139-47. PubMed ID: 19063700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antiviral therapy: from influenza to Pfeiffer's disease].
    Salzberger B
    Internist (Berl); 2006 Dec; 47(12):1245-50. PubMed ID: 17009040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What clinicians need to know about antiviral drugs and viral resistance.
    Hodinka RL
    Infect Dis Clin North Am; 1997 Dec; 11(4):945-67. PubMed ID: 9421709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency.
    Mejías A; Chávez-Bueno S; Ríos AM; Aten MF; Raynor B; Peromingo E; Soni P; Olsen KD; Kiener PA; Gómez AM; Jafri HS; Ramilo O
    Antimicrob Agents Chemother; 2005 Nov; 49(11):4700-7. PubMed ID: 16251314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Respiratory syncytial virus].
    Tsutsumi H
    Uirusu; 2005 Jun; 55(1):77-84. PubMed ID: 16308533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mismatched double-stranded RNA: polyI:polyC12U.
    Adis Editorial
    Drugs R D; 2004; 5(5):297-304. PubMed ID: 15357629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview on different classes of viral entry and respiratory syncitial virus (RSV) fusion inhibitors.
    Murineddu G; Murruzzu C; Pinna GA
    Curr Med Chem; 2010; 17(11):1067-91. PubMed ID: 20156158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palivizumab in the prevention of respiratory syncytial virus disease.
    Krilov LR
    Expert Opin Biol Ther; 2002 Oct; 2(7):763-9. PubMed ID: 12387675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral prophylaxis and treatment (excluding HIV therapy).
    Waugh SM; Pillay D; Carrington D; Carman WF
    J Clin Virol; 2002 Dec; 25(3):241-66. PubMed ID: 12423690
    [No Abstract]   [Full Text] [Related]  

  • 19. Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper.
    Esposito S; Abu-Raya B; Bonanni P; Cahn-Sellem F; Flanagan KL; Martinon Torres F; Mejias A; Nadel S; Safadi MAP; Simon A
    Front Immunol; 2021; 12():708939. PubMed ID: 34456918
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.